Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients

Exclusion Criteria

• •Any diagnosis of active acute, chronic, or sub-chronic kidney or liver disease.
• •Documented acute prostatitis, symptomatic or severe benign prostatic hyperplasia (BPH) or urinary tract infections.
• •Patients with uncontrolled diabetes or hypertension.
• •Patients with active non-prostate malignancy.
• •Patients with contraindications for MRI including implantable pace makers, cochlear implants.
• •Patients with uni- or bilateral hip prosthesis.
• •Subjects with other significant medical conditions that would create unacceptable operative risk, compromise retention on study or compromise study related assessments.
• •Major surgery within 4 weeks prior to entry on this study or patients who have not recovered from side effects of such therapy.
• •Prostate biopsy within 4 weeks prior to entry on this study in which inflammation might affect MRI result.
• •Subjects who received or will receive any other MRI contrast agent within 48 hours prior to MT218 injection or up to 24 hours after MT218 injection.
• •Is determined by the investigator that the patient is clinically unsuitable for the study.
• •Is incapable of understanding the language in which the information for the patient is given.
• •Participation in a concurrent clinical trial or in another trial within the past 30 days.